A drug called streptozocin is used to treat pancreatic cancer that has spread to other parts of the body
For
advanced islet-cell carcinoma, the combination of streptozocin and fluorouracil
has become the standard treatment. However, doxorubicin, a drug that is
structurally similar to streptozocin but causes less vomiting, has also been
shown to be effective against this type of tumor.
We
randomly assigned 105 patients with advanced islet-cell carcinoma to one of
three treatment regimens in this multicenter trial: streptozocin plus
fluorouracil, streptozocin plus doxorubicin, or chlorozotocin alone. The 31
patients who did not respond to the treatment were switched to chlorozotocin alone
or one of the combination regimens.
What
is the purpose of Streptozocin?
Streptozocin is used to treat pancreas cancer
that has progressed or spread to other parts of the body. Streptozocin belongs
to a class of drugs known as alkylating agents. It works by slowing or stopping
cancer cell growth in your body.
Where can I find streptozotocin?
Streptozotocin
(STZ) is a naturally occurring chemical derived from Streptomyces achromogenes
that is particularly toxic to the pancreatic insulin-producing beta cells in
mammals.
Streptozocin was discovered to be selectively
toxic to pancreatic islet beta cells, which normally regulate blood glucose
levels by producing the hormone insulin. This suggested that the drug could be
used as an animal model of diabetes and as a medical treatment for beta-cell
cancers. The National Cancer Institute investigated the use
of streptozocin in cancer chemotherapy in the 1960s and 1970s. In
November 1976, Upjohn applied to the FDA for approval of streptozocin as a
treatment for pancreatic islet cell cancer, and approval was granted in July
1982. The drug was later marketed under the brand name Zanosar.
More recently, a growing body of research has
shown that insulin signaling dysfunction in type 2 diabetes significantly
increases the risk of cognitive impairment and Alzheimer's disease (AD)
progression. On this basis, direct administration of STZ into the brain (i.e.,
intracerebroventricular (ICV) infusion) has been used to develop an animal
model of brain insulin resistance in rodents to mimic the pathophysiology of
sporadic AD, which is the most common type of AD in humans.
Comments
Post a Comment